U.S. Biologics Contract Manufacturing Market Size & Outlook
The biologics contract manufacturing market in the United States is expected to reach a projected revenue of US$ 18,282.7 million by 2030. A compound annual growth rate of 10.6% is expected of the United States biologics contract manufacturing market from 2025 to 2030.
Revenue, 2024 (US$M)
$9,956.7
Forecast, 2030 (US$M)
$18,282.7
CAGR, 2025 - 2030
10.6%
Report Coverage
U.S.
U.S. Biologics Contract Manufacturing Market, 2018-2030 (US$M)
Global Market
Related Markets
U.S. biologics contract manufacturing market highlights
- The U.S. biologics contract manufacturing market generated a revenue of USD 9,956.7 million in 2024 and is expected to reach USD 18,282.7 million by 2030.
- The U.S. market is expected to grow at a CAGR of 10.6% from 2025 to 2030.
- In terms of segment, monoclonal antibodies (mabs) was the largest revenue generating product in 2024.
- Vaccines is the most lucrative product segment registering the fastest growth during the forecast period.
Biologics contract manufacturing market data book summary
| Market revenue in 2024 | USD 9,956.7 million |
| Market revenue in 2030 | USD 18,282.7 million |
| Growth rate | 10.6% (CAGR from 2025 to 2030) |
| Largest segment | Monoclonal antibodies (mabs) |
| Fastest growing segment | Vaccines |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Vaccines, Monoclonal Antibodies (mAbs), Recombinant Protein, Antisense, RNAi, & Molecular Therapy |
| Key market players worldwide | WuXi Biologics (Cayman) Inc, FUJIFILM Holdings Corp, Boehringer Ingelheim, Lonza Group Ltd, AbbVie Inc, Catalent Inc, Merck & Co Inc, Thermo Fisher Scientific Inc, Eurofins Scientific SE, Abzena, Samsung BioLogics |
Other key industry trends
- In terms of revenue, U.S. accounted for 31.2% of the global biologics contract manufacturing market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. biologics contract manufacturing market is projected to lead the regional market in terms of revenue in 2030.
- U.S. is the fastest growing regional market in North America and is projected to reach USD 18,282.7 million by 2030.
No credit card required*
Publish Date: Apr 14, 2025
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Biologics Contract Manufacturing Market Scope
Biologics Contract Manufacturing Market segmentation & scope
Others
Others
Biologics Contract Manufacturing Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| AbbVie Inc | View profile | 50,000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | www.abbvieinvestor.com |
| Lonza Group Ltd | View profile | 18,000 | Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 | www.lonza.com |
| FUJIFILM Holdings Corp | View profile | 83,784 | 7-3, Akasaka 9-chome, Minato-ku, Tokyo, Japan, 107-0052 | www.fujifilmholdings.com |
| Thermo Fisher Scientific Inc | View profile | 122,000 | 168 Third Avenue, Waltham, MA, United States, 02451 | www.thermofisher.com |
| Eurofins Scientific SE | View profile | 61,798 | 23 Val Fleuri, Luxembourg, Luxembourg, L-1526 | www.eurofins.com |
| Merck & Co Inc | View profile | 72,000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | www.merck.com |
| Boehringer Ingelheim | View profile | 10001+ | Ingelheim Am Rhein, Rheinland-Pfalz, Germany, Europe | www.boehringer-ingelheim.com/ |
| WuXi Biologics (Cayman) Inc | View profile | 12,740 | No. 108, Meiliang Road, Mashan Binhu District, Wuxi, China, People's Republic of, 214092 | www.wuxibiologics.com |
| Catalent Inc | View profile | 17,219 | 14 Schoolhouse Road, Somerset, NJ, United States, 08873 | www.catalent.com |
| Samsung BioLogics | View profile | 1001-5000 | Incheon, Inch'on-jikhalsi, South Korea, Asia | www.samsungbiologics.com/ |
U.S. Biologics Contract Manufacturing Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Biologics Contract Manufacturing Market Outlook will help companies and investors design strategic landscapes.
Monoclonal Antibodies (Mabs) was the largest segment with a revenue share of 58.27% in 2024.
Horizon Databook has segmented the U.S. biologics contract manufacturing market based on vaccines, monoclonal antibodies (mabs), recombinant protein, antisense, rnai, & molecular therapy covering the revenue growth of each sub-segment from 2018 to 2030.
- U.S. Biologics Contract Manufacturing Market Product Outlook (Revenue, USD Million , 2018-2030)
- Vaccines
- Monoclonal Antibodies (mAbs)
- Recombinant Protein
- Antisense, RNAi, & Molecular Therapy
- Others
- U.S. Biologics Contract Manufacturing Market Indication Outlook (Revenue, USD Million , 2018-2030)
- Autoimmune Diseases
- Metabolic Diseases
- Neurology
- Infectious Diseases
- Oncology
- Cardiovascular Disorders (CVDs)
- Others
Reasons to subscribe to Biologics Contract Manufacturing Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Biologics Contract Manufacturing Market Outlook databook
- Our clientele includes a mix of Biologics Contract Manufacturing Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. Biologics Contract Manufacturing Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into U.S. Biologics Contract Manufacturing Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.
U.S. Biologics Contract Manufacturing Market, 2018-2030 (US$M)
U.S. biologics contract manufacturing market statistics, by product, 2018-2030 (US$M)
